Exclusive Report – According to two sources, the first liquefied natural gas production line of Qatar Energy’s NFE project is ready and about to start operation.
路透社2026/10/07 12:41According to two sources familiar with the matter, the first liquefied natural gas (LNG) production line under the "North Field East" expansion project by QatarEnergy is now ready and about to start operation, with the first batch of natural gas expected to be produced in November. This could provide Qatar with a way to restore some of the output lost due to attacks from Iran.
Marwa Rashad
Reuters London, October 7 - According to two informed sources, QatarEnergy's first liquefied natural gas (LNG) production line under the "North Field East" expansion project is ready and about to be put into operation, with the first batch of natural gas expected to be produced in November. This could provide a way for Qatar to recover some of the output lost due to attacks by Iran.
(To assist non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court
October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)
BUZZ-KeyBanc upgrades Corteva rating to "Overweight"; stock price rises
On October 7, KeyBanc upgraded the rating of agricultural technology company Corteva Inc (CTVA.N) from "Sector Weight" to "Overweight." CTVA rose 1.6% in pre-market trading to $14.1. The brokerage pointed out that new product launches, cost reductions, and improvements in farmers' economic conditions will be strong growth drivers for 2028-2029. The company’s ample cash reserves enable it to flexibly fund growth initiatives, stock buybacks, and potential acquisitions. Out of 23 brokerages, 16 have given the stock a "Buy" or higher rating, and 7 have rated it "Hold." The median target price is $18. As of the previous trading day's close, the stock had gained 38.3% year to date.
Antofagasta’s Centinela strike adds copper supply risk
Elon Musk personally defines Terafab: TSMC can at most "sublease a portion," operation is out of the question.
Musk clarified that Terafab will be independently constructed and operated, with TSMC possibly subleasing part of the site; Intel will be involved in technology development and will supply Tesla and SpaceX AI.
